ATMS: AI 评分 51/100 — AI 分析 (4月 2026)

Artemis Therapeutics Inc. is a shell company with no significant operations, previously involved in developing agents for infectious diseases. The company's financials reflect its current state, with a high negative P/E ratio and substantial negative profit margin.

Key Facts: AI Score: 51/100 Sector: Financial Services

公司概况

概要：

Artemis Therapeutics Inc., a shell company in the financial services sector, lacks significant ongoing operations after previously focusing on infectious disease treatments. Based in New York, the company's current financial metrics, including a negative P/E ratio of -21032.59 and a negative profit margin of -434.4%, reflect its dormant status.

ATMS是做什么的？

Artemis Therapeutics Inc., based in New York, operates primarily as a shell company, currently without significant business operations. Historically, the company focused on the development of therapeutic agents aimed at preventing and treating severe and life-threatening infectious diseases. However, this activity has ceased, and the company now exists as a subsidiary of Tonak Ltd., with minimal operational footprint. Founded with the intention of addressing critical needs in infectious disease management, Artemis Therapeutics aimed to create innovative solutions for a global health challenge. The company's transition to a shell corporation reflects a strategic shift away from its original focus, leaving it with a small team managing its limited assets and obligations. Artemis Therapeutics' current market position is characterized by its lack of active product development or revenue generation, making it distinct from other entities in the financial services sector.

ATMS的投资论点是什么？

Investing in Artemis Therapeutics Inc. (ATMS) presents a highly speculative scenario given its status as a shell company with no significant operations. The company's negative P/E ratio of -21032.59 and a profit margin of -434.4% underscore its financial challenges. Any investment would rely on potential future acquisitions or a strategic pivot that could revitalize the company. The low market capitalization of $0.06 billion reflects the market's current valuation of its limited assets and future prospects. Growth catalysts are contingent on identifying new business opportunities or undergoing a reverse merger. Investors should carefully assess the risks associated with OTC-traded shell companies before considering an investment in ATMS.

ATMS在哪个行业运营？

Artemis Therapeutics Inc. operates within the shell company segment of the financial services industry. These companies are often characterized by minimal operations and are frequently used for reverse mergers or acquisitions. The market for shell companies is driven by entities seeking expedited access to public markets. The competitive landscape includes other shell companies like AOAO, BHAC, CLOE, IRAA, and JMTM, all vying for similar opportunities. The industry is subject to regulatory scrutiny due to the potential for misuse, requiring careful due diligence and compliance.

Shell Companies

Financial Services

ATMS有哪些增长机遇？

Reverse Merger: Artemis Therapeutics could pursue a reverse merger with a private company seeking to go public without the traditional IPO process. The target company would acquire Artemis, effectively gaining a public listing. The timeline for such a transaction is highly variable, depending on finding a suitable target and completing due diligence, but can typically be completed within 6-12 months. The market for reverse mergers is substantial, offering a potentially quick route to public markets for private entities.
Acquisition Target: Artemis Therapeutics could be acquired by another company seeking to utilize its existing corporate structure and any remaining assets. This could provide a return to shareholders through a buyout. The timeline for an acquisition depends on identifying a suitable acquirer and negotiating terms, potentially occurring within the next 12-24 months. The market for corporate acquisitions is broad, influenced by strategic consolidation and market dynamics.
Strategic Pivot: Artemis Therapeutics could shift its business focus to a new sector, leveraging its existing corporate structure. This would require significant investment and strategic planning. The timeline for a successful pivot could extend over several years, requiring substantial capital and operational adjustments. The success of such a pivot depends on identifying a viable market opportunity and building a competitive advantage.
Asset Monetization: Artemis Therapeutics could monetize its remaining assets, if any, to generate cash flow. This might involve selling intellectual property or other holdings. The timeline for asset monetization can vary, depending on the nature of the assets and market conditions, potentially occurring within the next 6-12 months. The market for asset sales is influenced by prevailing economic conditions and buyer demand.
Capital Raise: Artemis Therapeutics could attempt to raise capital to fund new ventures or acquisitions. This would require convincing investors of the company's potential for future growth. The timeline for a successful capital raise depends on market conditions and investor sentiment, potentially taking several months to complete. The availability of capital is influenced by macroeconomic factors and investor risk appetite.

Market capitalization of $0.06 billion, indicating a small valuation.
P/E ratio of -21032.59, reflecting losses and minimal earnings.
Negative profit margin of -434.4%, highlighting significant operational losses.
Gross margin of 82.6%, which may be related to legacy assets or discontinued operations.
No dividend yield, consistent with the company's lack of profitability and operational activity.

ATMS提供哪些产品和服务？

Currently, Artemis Therapeutics Inc. operates as a shell company.
Previously, the company was involved in developing agents for infectious diseases.
The company is based in New York, New York.
Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.
The company has minimal ongoing business operations.
It explores potential opportunities for reverse mergers or acquisitions.

ATMS如何赚钱？

Currently, Artemis Therapeutics Inc. does not have an active business model.
Historically, the company aimed to generate revenue through the development and commercialization of infectious disease treatments.
Future revenue generation is contingent on identifying new business opportunities or undergoing a strategic pivot.

Historically, Artemis Therapeutics targeted healthcare providers and patients needing infectious disease treatments.
Currently, the company does not have active customers.
Potential future customers would depend on the company's new business direction.

Currently, Artemis Therapeutics does not possess a significant economic moat.
Historically, the company aimed to develop a moat through proprietary therapeutic agents.
Any future moat would depend on the company's ability to innovate and create competitive advantages in a new market.

什么因素可能推动ATMS股价上涨？

Upcoming: Potential reverse merger with a private company.
Upcoming: Possible acquisition by another company.
Ongoing: Exploration of strategic alternatives.
Ongoing: Management of existing assets.

ATMS的主要风险是什么？

Potential: Failure to identify viable business opportunities.
Potential: Regulatory scrutiny of shell companies.
Ongoing: Limited liquidity due to OTC listing.
Ongoing: Lack of financial transparency.
Ongoing: Negative profitability.

ATMS的核心优势是什么？

Existing corporate structure
Publicly listed status
Potential for reverse merger
Subsidiary of Tonak Ltd.

ATMS的劣势是什么？

No significant operations
Negative profitability
Limited assets
OTC listing

ATMS有哪些机遇？

Reverse merger with a private company
Acquisition by another company
Strategic pivot to a new sector
Monetization of remaining assets

ATMS面临哪些威胁？

Regulatory scrutiny of shell companies
Market volatility
Competition from other shell companies
Failure to identify viable business opportunities

ATMS的竞争对手是谁？

Asia Organics Acquisition Corp — AOAO is a shell company seeking acquisition targets. — (AOAO)
Bright Health Acquisition Corp. — BHAC is a shell company focused on the healthcare sector. — (BHAC)
Clover Leaf Capital Corp. — CLOE is a shell company pursuing business combinations. — (CLOE)
Income Research & Asset Allocation, Inc. — IRAA is a shell company seeking investment opportunities. — (IRAA)
JMTM Corp. — JMTM is a shell company looking for merger candidates. — (JMTM)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Shimon Citron
Headquarters: New York City, US
Employees: 4
Founded: 1998

AI Insight

AI analysis pending for ATMS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Artemis Therapeutics Inc. do?

Artemis Therapeutics Inc. currently operates as a shell company with no significant ongoing business operations. Previously, the company was involved in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. However, this activity has ceased, and the company is now focused on exploring potential opportunities for a reverse merger, acquisition, or strategic pivot. Its primary function is to maintain its corporate structure and evaluate potential future business directions.

What do analysts say about ATMS stock?

Given Artemis Therapeutics Inc.'s status as a shell company with limited operations, there is minimal analyst coverage. Key valuation metrics such as the negative P/E ratio of -21032.59 and a profit margin of -434.4% reflect its current financial challenges. Growth considerations are contingent on identifying new business opportunities or undergoing a strategic transformation. Investors should conduct thorough due diligence and carefully assess the risks associated with OTC-traded shell companies.

What are the main risks for ATMS?

The main risks for Artemis Therapeutics Inc. include its limited liquidity due to its OTC listing, lack of financial transparency, and potential for price manipulation. As a shell company, it faces regulatory scrutiny and uncertainty regarding its future business direction. The company's negative profitability and lack of significant operations pose additional challenges. Investors should be aware of these risks and conduct thorough due diligence before considering an investment in ATMS.